Table 3b.
HPV genotypes covered by the bi-, quadri-, and nonavalent vaccine by histological diagnosis and race/ethnicity.
| All (%) | Non-Hispanic White | Non-Hispanic Black | Hispanic | Asian | X2 or Fisher’s exact test P-value |
|
|---|---|---|---|---|---|---|
| All HPV Types | N=380a | N=206 | N=39 | N=142 | N=32 | <0.001 |
| ≤ CIN 1 | 217 (57.2%) | 42.8% | 67.6% | 78.8% | 33.3% | |
| CIN 2+ | 163 (42.8%) | 57.2% | 32.4% | 21.2% | 66.7% | |
| Bi-/Quadrivalent coverage | N=125 (32.9%) | N=79 (38.3%) | N=6 (15.4%) | N=28 (19.7%) | N=12 (37.5%) | 0.003c |
| ≤ CIN 1 | 53 (46.1%) | 34.7% | 80.0% | 73.1% | 44.4% | |
| CIN 2+ | 62 (53.9%) | 65.3% | 20.0% | 26.9% | 55.6% | |
| Nonavalent coverage | N=165 (43.4%) | N=77 (37.4%) | N=19 (48.7%) | N=54 (38.0%) | N=15 (46.9%) | 0.003 |
| ≤ CIN 1 | 71 (48.6%) | 36.4% | 50.0% | 68.6% | 27.3% | |
| CIN 2+ | 75 (51.4%) | 63.6% | 50.0% | 31.4% | 72.7% | |
| Not covered by any vaccineb | N=129 (33.9%) | N=50 (24.3%) | N=14 (35.9%) | N=60 (42.3%) | N=5 (15.6%) | 0.001c |
| ≤ CIN 1 | 93 (78.2%) | 65.2% | 85.7% | 90.9% | 25.0% | |
| CIN 2+ | 26 (21.8%) | 34.8% | 14.3% | 9.1% | 75.0% |
a
Histology data are missing for 39 of the 419 cases included in the overall analysis.
b
Participants were considered ‘not covered’ if no types in their sample were included in any vaccine.
c
P-value based on Fisher’s exact test.